#118, Making Tomorrow's Treatments Available Today with Michel van Harten MD, from myTomorrows

Guy Spigelman, EMEA Healthcare and Life Sciences Startups lead at AWS, sits down with Michel van Harten MD, CEO of myTomorrows, to explore how artificial intelligence is revolutionizing clinical trial recruitment. myTomorrows is transforming the patient-trial matching process, reducing hours of manual screening to mere minutes through sophisticated AI automation - all while maintaining exceptional accuracy standards.

1. How did a practicing physician become a digital health innovator?

• Driven by firsthand experiences with treatment access barriers, Michel van Harten MD, transitioned from clinical practice to leading myTomorrows, combining medical expertise with technological innovation to solve healthcare delivery challenges.

2. What makes myTomorrows' platform unique in the clinical trial space?

• The platform leverages advanced AI to create seamless connections between patients, physicians, and clinical trials, achieving an impressive 98% accuracy rate while reducing physician screening time by over 90%.

3. How does company culture contribute to patient impact?

• Monthly patient speakers and mission-focused initiatives keep their 110-person team deeply connected to their purpose. This values-driven approach helps attract top talent while maintaining sustainable growth.

4. What is the global reach of myTomorrows' solution?

• Operating across 125 countries with 2,200+ physicians, the platform has facilitated treatment access for nearly 15,000 patients through expanded access programs and clinical trial matching.

5. How has myTomorrows evolved from startup to scale-up?

• Through strategic pivots and technological advancement, myTomorrows has built a sustainable growth model, positioning themselves for growth equity funding and continued market expansion.

Learn more about myTomorrows at https://mytomorrows.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.